Share chart Zymeworks Inc.
Extended chart
Simple chart
About
Zymeworks Inc., биофармацевтическая компания, работающая на клинической стадии, занимается открытием, разработкой и коммерциализацией биотерапевтических средств для лечения рака.
More details| P/S | 59.02 |
|---|---|
| P/BV | 7.1 |
| EV/EBITDA | -10.83 |
| EBITDA | -0.1498 |
| Цена ао | 8.88 |
| Сайт | http://www.zymeworks.com |
| Число акций ао | 0.06886 млрд |
| Выручка | 0.0295 |
| Див.доход ао | 0 |
| P/E | 3.93 |
| ISIN | CA98985W1023 |
| Валюта | usd |
| IPO date | 2017-04-28 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Change price per day: | +1.2551% (12.35) |
|---|---|
| Change price per week: | -0.04% (12.51) |
| Change price per month: | +6.61% (11.73) |
| Change price per 3 month: | +49.05% (8.39) |
| Change price per half year: | +29.45% (9.66) |
| Change price per year: | +102.35% (6.18) |
| Change price per 3 year: | -57.36% (29.33) |
| Change price per 5 year: | -51.19% (25.62) |
| Change price per year to date: | +17.09% (10.68) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| EcoR1 Capital, LLC | 13437473 | 21.33 |
| BVF Inc. | 5870000 | 9.32 |
| Redmile Group, LLC | 5790230 | 9.19 |
| Morgan Stanley | 4861286 | 7.72 |
| Blackrock Inc. | 3923328 | 6.23 |
| Rubric Capital Management LP | 3475384 | 5.52 |
| Vanguard Group Inc | 2394712 | 3.8 |
| Credit Suisse Ag/ | 2303621 | 3.66 |
| Bnp Paribas Asset Management Holding S.a. | 1771776 | 2.81 |
| Farallon Capital Management Llc | 1756000 | 2.79 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares ESG Aware MSCI USA Small-Cap ETF | 0.05848 | 25.75 | 1.49366 |
| iShares Morningstar Small-Cap ETF | 0.01165 | 26.74 | 1.60498 |
| iShares Morningstar Small Cap Value ETF | 0.02408 | 25.43 | 2.50476 |
| iShares Micro-Cap ETF | 0.18553 | 24.67 | 1.54048 |
| iShares Russell 3000 ETF | 0.00124 | 33.65 | 1.43482 |
| iShares Morningstar Small-Cap ETF | 0.01165 | 26.74 | 1.60498 |
| iShares Morningstar Small-Cap Value ETF | 0.02408 | 25.43 | 2.50476 |
| iShares MSCI USA Small-Cap Min Vol Factor ETF | 0.11846 | 23.96 | 1.66828 |
| Principal Healthcare Innovators ETF | 0.0914 | 11.12 | 0.8416 |
| Future Tech ETF | 0.0914 | 11.12 | 0.8416 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Paul Moore Ph.D. | Chief Scientific Officer | 872.67k | 1968 (56 years) |
| Mr. Kenneth H. Galbraith C.A. | Chairman of the Board & CEO | 1963 (61 year) | |
| Ms. Leone D. Patterson M.B.A. | CFO, EVP & Chief Business Officer | 1962 (62 years) | |
| Mr. Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | 1970 (54 years) | |
| Mr. Daniel Dex J.D., Ph.D. | Senior VP, Corporate Secretary & General Counsel | ||
| Diana Papove | Senior Manager of Corporate Communications | ||
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development | ||
| Ms. Laura O'Connor | Vice President of Human Resources & DEI | ||
| Dr. Jeffrey Smith M.D. | Executive VP & Chief Medical Officer | ||
| Dr. Josemund Menezes MBBS | Managing Director of Early-Stage Development for Asia Pacific |
Address: Canada, Vancouver, BC VH V, 1385 West 8th Avenue - open in Google maps, open in Yandex maps
Website: http://www.zymeworks.com
Website: http://www.zymeworks.com
